BrainsWay Ltd. announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS?) for the treatment of late-life depression. The data were highlighted in an article entitled, ?Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression,? that was published in the Journal of Clinical Medicine, an international, peer-reviewed, open access journal.

The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD). In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay?s proprietary H1 Coil. The results showed a 79.4% response rate (=50% reduction in symptoms) and a 60.3% remission rate for those patients who had received at least 30 treatment sessions, and were based on the rating scale that was most utilized for each individual patient.

The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023. BrainsWay?s existing FDA depression labeling does not extend to patients aged over 68, and the results of this study are subject to further review by the FDA.